Interleukin Genetics Announces Conference Call to Discuss First Quarter 2016 Financial Results

WALTHAM, Mass., May 10, 2016 (GLOBE NEWSWIRE) -- Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and webcast on Monday, May 16, 2016, at 8:30 a.m. Eastern Time to provide a corporate update and discuss the Company’s first quarter ended March 31, 2016 financial results.

Monday, May 16th, 8:30 a.m. Eastern Time
Dial in (domestic):877-324-1976
Dial in (international):631-291-4550
Conference ID:5524079

A live webcast will also be available at the Investors section of the Company’s website at The webcast will be archived following the call at

About Interleukin Genetics
Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions. The products empower individuals and their healthcare providers to manage existing health and wellness through genetics-based insights and actionable guidance. Interleukin Genetics leverages its research, intellectual property, and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The company markets its tests through healthcare professionals, partnerships with health and wellness companies, and other distribution channels. Interleukin Genetics’ lead products include its proprietary PerioPredict® genetic test for periodontal disease and its Inherent Health® line of genetic tests. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvements Amendments (CLIA). For more information, please visit

Investor Contact: Hans Vitzthum LifeSci Advisors, LLC. (212) 915-2568 Media Contact: Jennifer Moritz Zer0 to 5ive for Interleukin Genetics (917) 748-4006

Source:Interleukin Genetics, Inc.